Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
University of Virginia
Study ID
NCT00265928
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bortezomib — DRUG
  • rituximab — DRUG
  • antibody therapy — PROCEDURE
  • biological therapy — PROCEDURE
  • enzyme inhibitor therapy — PROCEDURE
  • monoclonal antibody therapy — PROCEDURE

Study Details

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab works in treating patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, including Waldenstrom's macroglobulinemia.

Key Dates

Status verified
Jan 2007

Study Design

Enrollment
46 participants (estimated)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
University of Virginia Cancer Center at UV Health SystemCharlottesvilleVirginia22908-

Find similar trials in Charlottesville, VA

By research site
University of Virginia Cancer Center at UV Health System· Charlottesville, VA

Related Studies